Titan Pharmaceuticals
Titan is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology.
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 2978 % | (45 %) | 34 % | (68 %) | (96 %) | (98 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (119 %) | (497 %) | (110 %) | (642 %) | (16732 %) | (892000 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (136 %) | (456 %) | (377 %) | (575 %) | (17010 %) | (556900 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 113 % | 201 % | 122 % | 373 % | 7930 % | 191300 % | - |
Source: Company filings or news article
Related Content
Titan Pharmaceuticals is a specialty pharmaceuticals company focused on developing innovative therapeutics for chronic diseases. Utilizing its proprietary ProNeura platform, Titan offers long-term, continuous drug delivery solutions. The company's flagship product, Probuphine, is a six-month buprenorphine implant approved by the U.S. Food and Drug Administration for the maintenance treatment of opioid addiction. Titan operates in the pharmaceutical industry, targeting healthcare providers and patients requiring long-term medication management. The business model revolves around the development, approval, and commercialization of its drug delivery systems, generating revenue through product sales and potential partnerships. Titan's approach aims to provide stable, non-fluctuating medication levels, enhancing patient compliance and outcomes.
Keywords: specialty pharmaceuticals, chronic diseases, continuous drug delivery, ProNeura, opioid addiction, buprenorphine implant, FDA approved, healthcare providers, medication management, patient compliance.